Additionally, we examined the androgen sensitive, LNCaP prostate cancer cells and found significant inhibitory effects in agreement with findings by Petiwala et al. [60], while LNCaP cells lack the PTEN tumor suppressor, they are androgen responsive and therefore susceptible to cancer treatments such as androgen deprivation therapy [73]. The gene discussed is PTEN; the disease is cancer.